Corporate Information

Stemrim History
Oct. 2006 Established a company aiming to develop new drugs based on the discovery of bone marrow multi-potent stem cell mobilization factors identified by Professor Katsuto Tamai of the Graduate School of Medicine, Osaka University.
Apr. 2007 Started collaborative research with Osaka University. We have since continued to create intellectual property from the results of research.
Oct. 2008 Won a research grant from Japan Science & Technology Agency (JST), Industry-Academic Collaborative Seed Innovation Program.
Dec. 2009 Won a research grant from JST, “A-STEP (Adaptable and Seamless Technology Transfer Program through Target-driven R&D)”
Apr. 2010 Transferred our head office to Saito Bio Incubator (Ibaraki City, Osaka Prefecture) and set up a laboratory there.
Concluded a collaborative research contract with Shionogi & Co., Ltd. for research into bone marrow-derived stem cell mobilizing factor.
Nov. 2011 Won a research grant from JST, “A-STEP (Adaptable and Seamless Technology Transfer Program through Target-driven R&D)”
June 2012 Opened Kobe Lab in Port Island, Kobe. Expanded the capacity to perform drug efficacy tests using disease model animals.
July 2013 Expanded the laboratory in Saito Bio Incubator, expanded animal experiment facilities and absorbed the function of Kobe Lab.
Dec. 2013 Won a research grant from JST, “A-STEP (Adaptable and Seamless Technology Transfer Program through Target-driven R&D)”.
Apr. 2014 Adopted as a joint research project of The Center of Medical Innovation and Translational Research (CoMIT), Osaka University Graduate School of Medicine.
May 2014 Won a research grant from the New Energy and Industrial Technology Development Organization (NEDO), Innovation Commercialization Venture Support Project.
Nov. 2014 Concluded a licensing contract with Shionogi & Co., Ltd. for HMGB1 peptides (Redasemtide).
Aug. 2015 An investigator-initiated phase 1 clinical trial of Redasemtide started at Osaka University.
Dec. 2017 An investigator-initiated phase 2 clinical trial of Redasemtide in patients with Dystrophic Epidermolysis Bullosa(DEB) started.
July 2018 Changed our company name to StemRIM Inc.
Apr. 2019 A corporate phase 2 clinical trial of Redasemtide in patients with Acute Ischemic Stroke started at Shionogi & Co., Ltd.
Aug. 2019 Listed on the Tokyo Stock Exchange Mothers
Apr. 2020 An investigator-initiated phase 2 clinical trial of Redasemtide in patients with DEB has been completed.
June 2020 Established a new R&D base, “StemRIM Institute of Regeneration-Inducing Medicine, Osaka University”.
Sep. 2020 The grant project titled 'Development of Therapeutics for Novel Coronavirus Infection (COVID-19) - Third Call' has been awarded by AMED (Japan Agency for Medical Research and Development).
Nov. 2020 An investigator-initiated phase 2 clinical trial of Redasemtide in patients with Osteoarthritis of the knees has started at Hirosaki University.
Nov. 2020 An investigator-initiated phase 2 clinical trial of Redasemtide in patients with Chronic Liver Disease has started at Niigata University.
Feb. 2021 A trilateral research agreement has been signed between Shiseido Co., Ltd., Osaka University, for anti-aging research project related to the skin.
July 2022 An additional investigator-initiated phase 2 clinical trial of Redasemtide in patients with DEB has started.
Mar. 2023 A global phase 2b clinical trial of Redasemtide in patients with Acute Ischemic Stroke has started at Japan and North America.